Relapsed/Refractory Non-Hodgkin Lymphomas
1 clinical trials · Condition
◉ Watch Relapsed/Refractory Non-Hodgkin Lymphomas
| Record | Firm | Date |
|---|---|---|
| Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL (NCT06331832) | IGM Biosciences, Inc. |
Track Relapsed/Refractory Non-Hodgkin Lymphomas automatically
Every clearance here is in the API, with alerts when new ones post.